Latest news

• Biogen’s R&D chief Ehlers heads for the exit

  The Alzheimer’s programmes were the centrepiece of Biogen’s pipeline, and while one Eisai-partnered anti-amyloid candidate (BAN2401) remains in late-stage development with data due in 2022 there

• Biogen and Eisai drop Alzheimer’s drug elenbecestat

  now have only one amyloid-targeting drug left in the pipeline– a phase 3 study of amyloid-targeting candidate BAN2401, which remains unaffected by the discontinuation, with results set to read ... BAN2401 was shown to reduce disease progression by

• Undeterred by aducanumab failure, Eisai and Biogen plough on

  BAN2401 has been seen as something of an also-ran in the Biogen/Eisai pipeline, particularly after reporting confusing results in a phase 2b trial last year. ... there is now a shift towards thinking about the different forms of amyloid in the brain,

• Biogen and Eisai pull plug on Alzheimer’s drug

  The partners have a similar candidate, BAN2401, being studied in prodromal and mild Alzheimer’s patients, though its future must now also be under review.

• Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

  Also considering a trial in preclinical Alzheimer’s subjects. Biogen and Eisai spent the latter half of 2018 defending phase 2b results with their Alzheimer’s disease candidate BAN2401 against sceptics, ... s disease, while BAN2401 binds to and